Related Experiment Video
Updated: Jun 20, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Anne Monette1, Sarah Warren2, J Carl Barrett3
1Lady Davis Institute for Medical Research, Montreal, Québec, Canada.
Abstract:
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer progression. For these patients, while subsequent immunotherapies that either target a different axis of immune biology or non-immune combination therapies are reasonable treatment options, the lack of predictive biomarkers to follow-on agents is impeding progress in the field. This review summarizes the current knowledge of mechanisms driving resistance to PD-(L)1 therapies, the state of biomarker development along this axis, and inherent challenges in future biomarker development for these immunotherapies. Innovation in the development and application of novel biomarkers and patient selection strategies for PD-(L)1 agents is required to accelerate the delivery of effective treatments to the patients most likely to respond.
Insights
Immunotherapy targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-(L)1) axis shows promise, but resistance limits effectiveness. Novel biomarkers are crucial for identifying patients who will benefit from PD-(L)1 therapies.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Programmed cell death protein-1/programmed death-ligand 1 (PD-(L)1) axis inhibitors represent a major advance in cancer treatment.
- However, primary and acquired resistance to PD-(L)1 therapies significantly limits their clinical efficacy in many patients.
Purpose of the Study:
- This review synthesizes current understanding of resistance mechanisms to PD-(L)1 therapies.
- It also examines the current landscape and future challenges in developing predictive biomarkers for these immunotherapies.
Main Methods:
- Literature review of studies on PD-(L)1 resistance mechanisms.
- Analysis of current biomarker development strategies for PD-(L)1 inhibitors.
- Discussion of challenges in patient selection for immunotherapy.
Main Results:
- Multiple mechanisms contribute to primary and acquired resistance to PD-(L)1 blockade.
- Existing biomarkers have limitations in predicting response to PD-(L)1 therapies.
- Significant challenges exist in developing and validating novel biomarkers.
Conclusions:
- Overcoming resistance to PD-(L)1 therapies requires a deeper understanding of underlying biological mechanisms.
- Innovation in biomarker development and patient selection strategies is essential.
- Accelerating the delivery of effective immunotherapy to responsive patients necessitates novel approaches.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021